|
Synonyms: MAA-868 | MAA868 | NVS250519
Compound class:
Antibody
Comment: Abelacimab (MAA868) is a humanized monoclonal antibody that binds to the catalytic domain of both coagulation factor XI (FXI, F11) and activated FXI (FXIa) [3], and which was designed for antithrombotic potential. It locks FXIa into a conformation that cannot be activated by FXIIa or thrombin [1-2]. Inhbiting FXI/FXIa produces anticoagulant effects without adversly affecting normal hemostasis. Anti-FXI mAbs offer an alternative FXI-targeting strategy to investigational small molecule FXI inhibitors like asundexian and milvexian. Osocimab is another clinical stage anti-FXI mAb.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| References |
|
1. Koch AW, Schiering N, Melkko S, Ewert S, Salter J, Zhang Y, McCormack P, Yu J, Huang X, Chiu YH et al.. (2019)
MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans. Blood, 133 (13): 1507-1516. [PMID:30692123] |
|
2. Weitz JI, Chan NC. (2019)
MAA868 locks factor XIa in a zymogen-like state. Blood, 133 (13): 1393-1394. [PMID:30923107] |
|
3. Yi BA, Freedholm D, Widener N, Wang X, Simard E, Cullen C, Al-Saady NM, Lepor NE, Coulter S, Lovern M et al.. (2022)
Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa. J Thromb Haemost, 20 (2): 307-315. [PMID:34714969] |
